BALTIMORE - December 6, 2022 - (Newswire.com)

Protenus, the nation's leading healthcare compliance analytics technology platform provider, announced today the expansion of its revenue operations team and the addition of a drug diversion prevention subject matter expert.

"We're excited to expand our team with seasoned healthcare and technology industry professionals to help propel us further into our era of unprecedented growth," stated Nick Culbertson, Protenus CEO & Co-Founder. "Our new CRO, Cambrey Jordan, brings a winning combination of deep healthcare technology experience and a proven track record of excellence in leadership that will be instrumental in guiding our sales team to reach its full potential."   

"After nearly 18 years in the healthcare technology field, my passions remain the same: to improve the quality of care, access to care, and the privacy of all patients," said Cambrey, who also holds an Executive MBA in Healthcare Leadership from the University of Tennessee, Knoxville. "At Protenus, I look forward to leveraging my extensive sales and leadership experience to elevate our vision — that the delivery of care should be without risk — and helping hospitals and health systems across the U.S. achieve their strategic initiatives."

Along with the CRO position, Protenus has invested in roles that provide additional specialized knowledge in pharmacy and drug diversion monitoring and healthcare technology consultative selling — Adam Beeler, PharmD MS, joined as Director, Pharmacy Services and Tom Chelchowski as VP, Sales. Protenus is committed to supporting its community of employees and customers by adding key subject matter experts to further the organization's growth and provide valuable customer guidance backed by real-world expertise. 

About Protenus

Protenus harnesses the power of AI to provide healthcare organizations with scalable risk-reduction solutions that drive the safest patient outcomes while protecting the reputation of the organizations. We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients. Empowering healthcare to eliminate risk is at the heart of all we do. 

Founded in 2014, Protenus is a three-time winner of Forbes' America's Best Startup Employers, is a Great Place to Work®-Certified company, and was named one of 2021 CBInsights Digital Health 150, one of The Best Places to Work in Healthcare by Modern Healthcare, and one of the Best Places to Work in Baltimore by the Baltimore Business Journal and the Baltimore Sun. Learn more at Protenus.com and follow us on Twitter @Protenus.

Contact Information:
Amanda Rogers
Marketing Content Writer
[email protected]


Press Release Service by Newswire.com

Original Source: Protenus Expands Sales Team With CRO and VP, Deepens Expertise With Director, Pharmacy Services

Rapha Dental LLC is one of the best-growing practices in Cinnaminson, offering a range of oral health services to families in New Jersey.

CINNAMINSON, N.J. - December 6, 2022 - (Newswire.com)

Rapha Dental in New Jersey is accepting new patients and has dental services for the entire family. Dr. (Mark) Mock In Huh is known for his gentle and affordable dentistry. 

Rapha Dental offers a range of important services from general dentistry to orthodontics and cosmetic procedures. The doctor performs dental implant surgery, extractions, root canals, and restorative procedures and handles pediatric dental care. Rapha Dental boasts state-of-the-art technology in its offices including:

• A 3D CT scanner.
• Laser technology.
• A digital scanner for crown impressions.

In addition to routine, gentle dentistry, Dr. Huh and the team at Rapha Dental are capable of treating a variety of problematic oral health conditions on-site. These include abscessed teeth, chipped teeth, tooth sensitivity, jaw pain, Burning Mouth Syndrome, teeth grinding (bruxism), bad breath, tooth erosion and more.

The office of Rapha Dental has also invested in a comfortable dental chair that meets the needs of a wide range of patients. The clinic staff understands that some patients have back or neck pain that makes sitting in regular dental chairs uncomfortable. Others suffer from vertigo, which can be problematic in the reclined position. The dental chair at Rapha Dental in New Jersey is the A-dec 500 dental chair. This chair uses the science of pressure mapping and thoughtful cushioning to minimize pressure points and support the patient's body. The chair also has a virtual pivot feature that prevents patients from needing to readjust their position in the chair after it's raised or lowered. 

The family dental services at Rapha Dental are priced competitively, and they accept most PPO insurance policies. For patients without an insurance plan, the clinic offers financing and In-House Membership options to ensure dental care is available to everyone. 

Dr. Hun was born in Seoul, South Korea, and earned his Bachelor of Arts in Chemistry at the University of Washington. He holds a Doctor of Dental Medicine degree from the University of Pennsylvania School of Dental Medicine and graduated in 2009 with outstanding performance in the pre-doctoral endodontic program. He also has surgical experience gained from a residency at the Bronx Lebanon Hospital Center. 

To book an appointment or inquire about dental services in Cinnaminson, NJ, interested individuals can visit Rapha Dental's website. The clinic is located at 700 route 130 N Suite 204 Cinnaminson, NJ 08077 and is open Monday to Thursday and on Saturdays. 

Contact Information:
Mark Huh
Owner
[email protected]
8568298668


Press Release Service by Newswire.com

Original Source: Rapha Dental LLC Opens 2 Additional Treatment Rooms in Cinnaminson, New Jersey

RALEIGH, N.C. - December 6, 2022 - (Newswire.com)

Pharmacy Quality Solutions (PQS), experts in healthcare quality measurement and improvement, is proud to announce that it has been selected as a winner of the top BioTech/HealthTech Company at the 2022 NC TECH Awards. Winners were recognized at the NC TECH Awards Gala on Tuesday, November 29, presented in conjunction with title sponsor Cherry Bekaert. 

Todd Sega, CEO of PQS, accepted the award on behalf of the company, whose mission is to drive quality measurement as the pathway to better patient health outcomes. PQS achieves this mission through their analytics and patient identification tool, EQUIPP^®. Their data-driven quality improvement technology creates opportunities for payers and providers to engage patients and achieve improved health outcomes. The EQUIPP^® platform connects 9 out of 10 Medicare lives to 95% of all community pharmacies, focusing on gaps in care and improving the quality of patient care. 

"This award represents the collective hard work of the entire PQS team, who has a relentless commitment to enable healthcare quality improvement and create innovative channels to help payers and providers focus on patients who need additional attention," Sega said. "Our team has spent most of 2022 re-architecting and launching the new EQUIPP^®, a big achievement as a company. To cap off 2022 with this distinguished NC Tech award is a great win and recognition for PQS."

The NC TECH Awards is North Carolina's only statewide technology awards program, recognizing companies and individuals who have demonstrated growth, innovation, and leadership.  For more information on the selection process, categories, finalists, winners, and the awards gala, visit www.nctech.org/awards.

"Since 1995, the NC Tech Awards has honored excellence and innovation throughout North Carolina, representing the best and brightest," said Brooks Raiford, president and CEO of NC TECH.  "As a winner, PQS has distinguished itself as a peer-leader and we are proud to recognize them as a 2022 NC Tech Awards winner."

About NC TECH

NC TECH is a not-for-profit, membership-driven trade association and the primary voice of the technology industry in North Carolina. NC TECH's mission is to foster growth and champion innovation in North Carolina's tech sector, while providing a voice for the tech community. NC TECH's membership includes close to 600 member companies, organizations and institutions employing more than 200,000 workers in North Carolina. For more information, visit nctech.org. 

About Pharmacy Quality Solutions, Inc. (PQS)

PQS aligns healthcare payers and pharmacies to achieve their shared goals of better patient outcomes and healthcare quality performance. As a neutral, trusted intermediary supporting the evolution of value-based care, PQS facilitates nationwide pharmacy-based care through our partners and the EQUIPP^® platform. Utilizing deep clinical pharmacy knowledge and nearly a decade of performance management experience, we help clients develop strategies, implement effective programs, and optimize the quality of healthcare for their Medicare, Medicaid, and commercial populations.

For more information on how PQS can support you, please visit www.pharmacyquality.com.

Contact Information:
David Simoneaux
Communications Specialist
[email protected]
919.767.9544


Press Release Service by Newswire.com

Original Source: PQS Wins Top BioTech/HealthTech Company Award

ZUG, Switzerland - December 6, 2022 - (Newswire.com)

nChain, one of the largest global blockchain solutions companies, today announces its partnership with Hataali, the world-leading cell and gene therapy platform from ATMPS Ltd. The partnership will see nChain's data integrity platform allow Hataali to access the most scalable and secure blockchain unprecedented in the precision medicine space. 

Hataali, is the most advanced, regulatory-compliant, medical data-sharing platform for personalised medicines in the Advanced Therapy Medicinal Products sector. A unique and patented platform which provides the most comprehensive capabilities and functionality.

The Hataali Platform enables all partners in cell and gene therapies, from hospitals, to labs, to clinics and specialized couriers, to communicate and coordinate in real time. The platform is a configurable solution that enables partner organizations in personalised medicine to ensure that data required for optimal patient outcomes can be shared between parties in a secure, confidential, and regulatory-compliant manner using advanced distributed ledger technology. 

Hataali, the winner of the CPHI Pharma Award 2022 and the BioNow Award, is a true end-to-end solution that provides full transparency of the treatment process by keeping an immutable record of the full chain of custody, identity, and condition, demonstrating who is responsible and what has been done at each stage of the process. 

"The instant permissioning, interoperability and analysis of data, securely between healthcare institutions can greatly improve treatment effectiveness and ensure patient safety. There's so much innovation in personalised medicine right now, but the full benefits of those treatments can't be realized if our data infrastructure lags and cannot reach their full potential with our fully digital Hataali platform. Digitisation has become an increasingly important issue for organisations which have become cost conscious and looking for efficiency," said ATMPS Ltd. Founder and CEO Raja Sharif. 

He added, "We are excited to partner with nChain to integrate our platform providing access to their blockchain which we believe offers a best-in-class solution for data integrity which is paramount in healthcare, and even more so when it comes to precision medicine."

Since 2015, nChain has focused on developing solutions and inventions for enterprise blockchain use and satisfying the data management needs of all industries. nChain's data integrity platform provides enterprises and governments access to the benefits of tamper-proof documents, auditable logs, and integrated key management into APIs, allowing organizations to focus on collecting and analyzing data rather than securing it.

"The time has come for us to rethink the approach to patient data utility and security. The rails of the healthcare system deserve as much innovation as the treatments themselves, otherwise, healthcare providers won't be effective in delivering those treatments. We're proud to partner with an organization at the forefront of revolutionizing the administration of cell and gene therapies, and are committed to helping them make a difference in the lives of their patients," commented nChain's CEO Hakan Yuksel. 

About ATMPS

ATMPS Ltd provides patented advanced technical solutions for healthcare companies in the Advanced Therapy Medicines Products sector, including CAR-T treatments, stem cell and gene treatments. ATMPS have a unique distributed ledger solution which provides immutable and incorruptible data and automation capabilities. The solution is operational, configurable and can provide data analytics modules. It can integrate with all LIMS, MES and legacy solutions. It provides full chain of custody, identity and condition of samples, treatments and assets which it tracks. It also schedules and co-ordinates the supply chain participants, as well as giving them information at the same time, in real time, from a "single source of truth." For more information, please visit ATMPS' website at https://www.atmps.net.

About nChain  

nChain is a leading global blockchain technology company and recently voted one of the Top 100 most innovative firms in the world. We offer software, consulting services and IP licensing for clients in various industries looking to benefit from the security and scalability of the blockchain. Our mission is to secure the internet of value. Founded in 2015, nChain employs more than 250 staff, holds over 400 patents and are the developers of the Bitcoin SV Node software, Teranode, LiteClient and more.

Contact Information:
Carlos Leira
Director, Marketing & Communications
[email protected]


Press Release Service by Newswire.com

Original Source: nChain Partners With ATMPS Ltd. to Power Their World-Leading Cell and Gene Therapy Platform Hataali

Presentation to include clinical data from a phase 2 study of Gruticibart (AB023), a factor XI-targeted antibody being developed for the treatment and prevention of thrombosis and inflammation

PORTLAND, Ore. - December 6, 2022 - (Newswire.com)

Aronora Inc., a clinical-stage biotechnology company developing next-generation therapeutics for blood clotting diseases, announced today that clinical data from a phase 2 study of Gruticibart will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, Dec. 10-13, 2022. 

Gruticibart (AB023) is a unique recombinant antibody that targets coagulation factor XI (FXI) and specifically inhibits FXI activation by factor XII without blocking its activation by thrombin. It has been specifically designed to treat and prevent blood clots without causing an increased bleeding risk. This phase 2 study evaluated the safety and efficacy of Gruticibart for the prevention of catheter-associated thrombosis in patients with cancer receiving chemotherapy. Additional information about the trial can be found at https://clinicaltrials.gov/ct2/show/NCT04465760.

Details of the oral presentation are as follows:
Title: Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Cancer Patients Undergoing Central Line Placement: A Phase 2 Clinical Trial
Publication Number: 518
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Cancer-associated Thrombosis: Risk Stratification, Prevention, and Treatment
Session Date: Sunday, Dec. 11, 2022
Session Time: 12-1:30 p.m. 
Presentation Time: 12:15 p.m.

Abstracts are available via the ASH meeting website at https://www.hematology.org/meetings/annual-meeting/abstracts. 

Preclinical and early clinical development has been partially supported by the National Heart, Lung, and Blood Institute and National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award numbers R44HL106919, R44HL128016, and R44AI088937. This content is solely the responsibility of Aronora and does not necessarily represent the official views of the NIH.
For more information, please visit www.aronorabio.com.
 

Contact Information:
Erik Tucker
President & CEO
[email protected]
(503) 530-6842


Press Release Service by Newswire.com

Original Source: Aronora Announces Clinical Data to Be Presented at the 64th American Society of Hematology Annual Meeting

Tech firms unite to address inefficiencies in virtual care integration

CHARLOTTE, N.C. - December 6, 2022 - (Newswire.com)

Today, Redox, the company setting the stage for composable healthcare, has partnered with Let's Talk Interactive, a technology company that develops virtual care solutions to make healthcare more accessible. Together Let's Talk Interactive (LTI) and Redox are addressing inefficiencies in virtual care and making the EHR/EMR integration experience seamless for healthcare systems.

Virtual care solutions enable healthcare systems to extend access to care, overcoming clinician shortages and burnout, while maintaining continuity of care and improving patient outcomes. However, a key barrier to telehealth deployment for many health systems is the ability to find an efficient path to telehealth implementation. On average, it takes hospitals 23 months to go from identifying the need for digital innovation to scaling that solution to meet the need (AMA). Integrating a new virtual care solution into a health system's current EHR alone can take 3-4 months.

LTI and Redox are addressing these inefficiencies head-on, cutting the virtual care integration time in half to 30 to 60 days. LTI's next-generation enterprise telehealth solution, TrustVideo, leverages Redox's integration expertise with any EHR/EMR system, resulting in the platform's efficient integration with existing workflows of healthcare systems. This enables healthcare systems to integrate virtual care faster than ever before and scale it across the entire system efficiently with no additional cost. 

"Virtual care has seen an unprecedented rise in the past couple of years," explains Redox VP of Product Bryan Dunn. "Patients and clinicians see the value of having virtual experiences composed just for them. At Redox, we're glad to help LTI make that happen at scale."

"We are thrilled to announce our partnership with Redox, a best-in-class partner whose integration expertise is unmatched," said Arthur Cooksey, CEO and Founder of Let's Talk Interactive. "Our collaboration has resulted in one of the most unique telehealth technology platforms on the market that can serve any medical use case. Together, we are serving our mission which is to make healthcare accessible for all people." 

About Redox 
Payers, providers, digital health companies, and other healthcare entities use Redox to produce differentiated experiences for patients and clinicians. Connecting to more than 30,000 healthcare organizations, Redox provides a composable software experience across the healthcare ecosystem. With our single API, product teams are empowered to build whatever they can imagine. Redox accelerates innovations that make healthcare data more useful than ever before.

About Let's Talk Interactive, Inc.
Let's Talk Interactive, Inc. (LTI) is an innovator in telehealth that has developed the most complete and configurable HIPAA-compliant telemedicine platform in the world.  

Through proprietary telehealth software, medical hardware, and provider network solutions, LTI gives those in need instant access to care. Headquartered in Charlotte, NC, the company ranked No. 496 on the 2022 Inc. 5000 annual list of fastest-growing companies. For more information about Let's Talk Interactive, visit visit www.letstalkinteractive.com.

Contact Information:
Caitlin Wolf
PR and Communications Executive, LTI
[email protected]
980-220-3777

Miona Short
Redox media contact
[email protected]


Press Release Service by Newswire.com

Original Source: Redox and Let's Talk Interactive Partner to Expand Access to Healthcare